Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
boston blog main
boulder/denver blog main
boulder/denver top stories
crispr
8
×
detroit blog main
detroit top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
8
×
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
indiana blog main
indiana top stories
fda
ipo
cancer
eli lilly
glaxosmithkline
novartis
biogen
clinical trials
deals
gene editing
gene therapy
startups
What
bio
roundup
new
crispr
life
moves
science
ceo
companies
ipo
millions
month
remains
talk
therapeutics
week
years
acquisitions
allogene
announced
approval
bails
becker
big
billions
biogen’s
biopharma
biopharmaceutical
black
bosley's
bosley’s
brand
bridge
bridgebio
bucks
cancer
capital
car
cas
collabs
Language
unset
Current search:
photo
×
" new york top stories "
×
crispr
×
" texas blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More